Apalutamide and Overall Survival in Prostate Cancer

Matthew R. Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris A. Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, Ji Youl Lee, Hiroji Uemura, Peter De Porre, Andressa A. Smith, Sabine D. Brookman-May, Susan Li, Ke Zhang, Brendan Rooney, Angela Lopez-Gitlitz, Eric J. Small

Research output: Contribution to journalArticlepeer-review

135 Scopus citations


Apalutamide increased overall survival and delayed time to initiation of cytotoxic chemotherapy versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Prior analyses had demonstrated clinically impactful improvement in metastasis-free survival, time to symptomatic progression, and second progression-free survival with apalutamide.

Original languageEnglish (US)
Pages (from-to)150-158
Number of pages9
JournalEuropean Urology
Issue number1
StatePublished - Jan 2021


  • Apalutamide
  • Nonmetastatic castration-resistant prostate cancer
  • Overall survival
  • Subsequent therapy
  • Time to cytotoxic chemotherapy

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Apalutamide and Overall Survival in Prostate Cancer'. Together they form a unique fingerprint.

Cite this